Kornimate/medical-research-clean huggingface dataset:
surgical incision closure method to prevent niche formation after cesarean section- randomized controlled trial

Conditions: Cesarean Section Complications; Uterine Bleeding

Summary: in the last decade we have been exposed to the complication of a caesarean section called a "niche". a niche is an anaerobic defect in the location of the cesarean section, which represents the discontinuity of the endometrium and myometrium. a niche is usually diagnosed by ultrasound, and can also be diagnosed by hysterosalpingogram or hysteroscopy. in the presence of a niche women suffer more frequently from irregular bleeding, dysmenorrhea, chronic pelvic pain, and dyspareunia. we believe that a combination of tissue ischemia and thinning of the scar tissue that forms, causes a niche to form. large randomized studies regarding the preferred surgical technique in cesarean section, including various methods of incision closure have found that there is no single method that is obviously superior. however, these studies did not examine niche formation as a complication of cesarean section. in this study we will examine whether a unique incision closure method reduces post-cesarean niche formation.


Eligibility criteria:
inclusion criteria: * women at first cesarean delivery * women who consent to the study exclusion criteria: * women who are having a repeat caesarean section * refusal to participate in the study * urgent or emergent cesarean delivery
clinical study of caffeine for apnea of prematurity

Conditions: Apnea of Prematurity

Summary: the aim of the present phase iii study is to evaluate the safety, efficacy and pharmacokinetics of caffeine citrate for treatment of apnea of prematurity in japan.


Eligibility criteria:
inclusion criteria: * postconceptional age between 28 weeks and 33 weeks, and over 24 hours after birth. * at least 6 episodes of apnea (\>20 seconds in duration) in 24 hours. * signed written informed consent from parent(s) or legal guardian(s). exclusion criteria: * apnea due to: hypoxic-ischemic encephalopathy, meningitis, seizures, grade iii or iv intracranial hemorrhage, cns depression from drugs administered to the mother during delivery, periventricular leukomalacia, pneumonia which does not improve even if it treats, hemoglobin\ 38.5 °c on 2 consecutive readings, rectal temperature\< 35 °c on 2 consecutive readings, obstructive apnea. * blood urea nitrogen \>20 mg/dl, serum creatinine \>1.5 mg/dl. * serum ast or alt \>3 times the upper limit of normal. * requirement of mechanically-assisted ventilation ( containing nasal cpap, nasal dpap). * previous treatment with methylxanthines within 7 days prior to study enrollment. * previous treatment with h2 antagonists (i.e., cimetidine or ranitidine) within 7 days prior to study enrollment. * receiving or experiencing the effects of cns-active medication at the time of enrollment. * participant of other clinical trial within 6 months. * inappropriate to enter this clinical trial judged by the investigator in charge.

Keywords: caffeine apnea prematurity
cold press test and post operative pain relationship

Conditions: Post-operative Pain, Acute; Pain Threshold

Summary: the goal of this clinical trial is to investigate whether it is possible to get a preliminary idea about the postoperative pain in the patient with the results of a practical cold press test applied to american society of anesthesiologists(asa) 1 and 2, healthy, male patients aged 16-35 before extraction of the lower third molar. the main question it aims to answer are: • can post-operative pain be predicted with an cold test that can be applied more practically than conventional quantitative sensory tests applied preoperatively? participants will need to keep their hands on ice for 240 seconds prior to third molar surgery. when they take their hands off the ice, they will be asked to describe their pain on the visual analog scale. after the operation, the participants are required to mark whether they use painkillers every 8 hours in their pain follow-up forms and the pain they feel according to the visual analog scale. depending on the endurance time of the participants to keep their hands on the ice; two different groups were determined as less than 240 sec and equal to 240 sec. the pain scores and the amount of painkiller use between these two groups were compared with each other.


Eligibility criteria:
inclusion criteria: * the impacted third molar should be class 1 or 2 and position b according to pell \& gregory classification. * the impacted third molar should be asymptomatic. * the impacted third molar should be located in the mandible and be in the mesioangular or vertical position. * to be male gender * to be in american society of anesthesiologists 1 or 2 classification * to be between the ages of 16-35 exclusion criteria: * intolerance to non-steroidal anti-inflammatory drugs * smoking more than 10 cigarettes a day * operation time exceeding 20 minutes * individuals who have performed third molar tooth extraction

Keywords: cold pressor test post-operative pain mandibular third molar
the effect of fascia therapy and transcutaneous fibrolysis on acute ankle sprain

Conditions: Acute Ankle Distortion

Summary: this study investigates the immediate effect of fascia therapy and transcutaneous fibrolysis in the treatment of an acute ankle sprain. these treatments will be compared to a placebo group.

ankle sprain is the most occurring sport related injury. in spite of the high prevalence of this injury and the often residual symptoms, there is a large variety in diagnostic approach and therapeutic protocols. concerning the treatment of an acute ankle sprain, it remains a challenge to minimize injury consequences on short and long term. in this study we investigate the immediate effect of two therapeutic techniques: fascia therapy and transcutaneous fibrolysis. they will be compared to a third group, who receives a placebo treatment. muscle strength, muscle vascularisation, muscle tenderness and joint position sense are measured before and after treatment. the purpose of this study is to contribute to the knowledge of treating acute ankle sprains.

Eligibility criteria:
inclusion criteria: * acute ankle sprain exclusion criteria: * none

Keywords: fascia therapy transcutaneous fibrolysis acute ankle distortion
exercises on cipn, fatigue, and quality of life in colon cancer patients receiving chemotherapy

Conditions: Experimental Study Designs

Summary: objective: cancer is one of the biggest global health threats. the incidence and mortality of colorectal cancer (crc) are increasing. the treatment of crc is mainly surgical resection, and the standard treatment of metastatic colorectal cancer is oxaliplatin chemotherapy, which is mainly a platinum agent (alkylating agent). oxaliplatin can exert its anti-cancer therapeutic effect by binding to cell dna, and become toxic to neurons, damaging large and small fibers outside the brain and spinal cord. causes peripheral neuropathy, which seriously affects the quality of life of patients. the purpose to develop the interventional and investigate intervention by exercise program of crc patients with regard to the improvement effect of peripheral neuropathy, fatigue and quality of life during the treatment. methods: experimental study designs were used, and samples were taken from a regional teaching hospital. the control group received routine care and maintenance of general daily activities; the experimental group received routine care and maintenance of general daily activities, and also received combined exercises, balance training and resistance exercises twice a week, 60 minutes each time, plus weekly 5 walking exercises, 30 minutes each time, for a total of 12 weeks, of which the exercise training during chemotherapy and hospitalization is performed under the supervision of the investigator, and 1 balance training and resistance exercise are performed for 60 minutes each time to ensure that the patient performs. the correctness and safety of exercises, and balance training and resistance exercises in combination with the home style. during the home exercises, the researchers will give weekly telephone interviews to understand the patient's exercise status, and indeed achieve the balance training and resistance exercises twice a week. all measurement tools and methods are implemented in accordance with consistent standard operations. the control group took pre-tests when the case was closed, without interventional measures, but also performed post-tests in the same way as the experimental group at 6 weeks, 8 weeks, 10 weeks, and 12 weeks in the interventional experimental group.


Eligibility criteria:
inclusion criteria: * diagnosed with colon cancer, were getting chemotherapeutic drugs with oxaliplatin. exclusion criteria: * bone metastasis, lower extremity lymphedema, cognitive dysfunction, musculoskeletal problems,and diabetic.
position changes during colonoscope withdrawal and polyp detection

Conditions: Colonic Polyp

Summary: the purpose of this study is to determine whether position changes during colonoscope withdrawal affects polyp detection rate. we hypothesize that positions change during scope withdrawal will increase polyp detection rate.


Eligibility criteria:
inclusion criteria: * outpatients undergoing colonoscopy * age 40 or greater exclusion criteria: * inpatient colonoscopy * unable to provide informed consent * unable to complete colonoscopy to cecum * previous bowel resection, inflammatory bowel disease, polyposis syndrome * musculoskeletal disorder or other mobility issue limiting effective patient position changes * inadequate bowel preparation

Keywords: detection
combining neuro-imaging and non-invasive brain stimulation for clinical intervention in opioid use disorder

Conditions: Opioid-Related Disorders; Heroin Dependence; Morphine Dependence

Summary: the overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the university of minnesota towards developing novel paired-neuromodulation approaches using transcrancial direct current stimulation (tdcs) for new addiction treatments that support long-term abstinence. this study will investigate whether the pairing of dorsolateral prefrontal cortex (dlpfc) stimulation and cognitive training can enhance functional connectivity between dlpfc and nucleus accumbens (nacc). we have identified higher functional connectivity between dlpfc and nacc in alcoholics that have successfully maintained abstinence for extended periods of time (7 years). this paired-neuromodulation approach can potentially be used as a therapeutic intervention to decrease substance use probability in addiction (e.g. opioid use disorder). the long term goal is to develop new addiction treatments that support long-term abstinence in opioid use disorder. the overall objective of this proposal is to enhance functional connectivity between dlpfc and nacc as a therapeutic intervention to enhance cognition and reduce substance use rates in opioid use disorder.


Eligibility criteria:
inclusion criteria: * current diagnosis of opioid use disorder * enrolled in a methadone treatment program for at least 2 months in hennepin healthcare and be clinically stable. * meet the diagnostic and statistical manual of mental disorders (dsm-v) diagnostic criteria for opioid use disorder * participants may have current comorbid drug use, but their primary substance use disorder diagnosis must to be based on opioid use. * participants must have the intention to remain in the methadone treatment program until the end of the intervention portion of the study. exclusion criteria: * any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness\>30 min, hiv) * head injury resulting in a skull fracture or a loss of consciousness exceeding 30 minutes (i.e., moderate or severe tbi) * any contraindications for tdcs or mri scanning (tdcs contraindication: actively receiving treatment for seizures or epilepsy; mri contraindications; metal implants, pacemakers or any other implanted electrical device, injury with metal, braces, dental implants, non-removable body piercings, pregnancy, breathing or moving disorder) * current active psychosis or mania * presence of a condition that would render study measures difficult or impossible to administer or interpret (e.g. current mania, active psychosis) * primary current substance use disorder diagnosis on a substance other than opioid except for caffeine or nicotine * current stimulant use disorder (need to be free of stimulant use for at least 1 month) * history of electroconvulsive therapy or cortical energy exposure within the past 12 months, including participation in any other neuromodulation studies * incarceration
a safety and efficacy study of xp19986 in subjects with spasticity due to spinal cord injury

Conditions: Muscle Spasticity

Summary: the purpose of this study is to evaluate efficacy and safety of treatment with xp19986 sustained release (sr) tablet compared to placebo in subjects with spasticity due to spinal cord injury

this is a multiple-dose, randomized, placebo-controlled crossover study of the efficacy and safety of xp19986 sr1 in subjects with spasticity due to spinal cord injury. three cohorts of subjects are randomized to receive xp19986 sr1 10 mg every 12 hrs or 20 mg every 12 hrs or 30 mg every 12 hrs in one treatment segment and placebo every 12 hrs in the alternate treatment segment. each subject serves as their own control in this cross-over study.

Eligibility criteria:
inclusion criteria: * spasticity secondary to traumatic spinal cord injury between c-5 and t-12 spinal cord levels, at least 12 months post-injury with a stable neurological deficit exclusion criteria: * traumatic brain injury or cognitive deficit of any etiology that may influence compliance with study procedures or outcome measures
efficacy of doxycycline & versus rifampin in treatment of rhinoscleroma

Conditions: Rhinoscleroma

Summary: the study is conducted to evaluate the efficacy of doxycycline (alone and in combination with ciprofloxacin) as an alternative to the regular regimen in treating rhinoscleroma, especially for cases with contraindication to the use of one or more of the regularly used drugs.

rhinoscleroma is a chronic granulomatous disease endemic in many eastern countries including egypt, its causative agent is a gram-negative bacillus, klebsiella rhinoscleromatis. low socioeconomic populations are the most affected.. there are four known stages of the lesion. the first of which the 'catarrhal stage' with purulent rhinorrhea, then there is the 'atrophic stage' with a picture similar to that of atrophic rhinitis. the next is the 'hypertrophic' or 'granulomatous' stage where there are bluish red rubbery nodules in any part along the distribution of the disease, and eventually the 'fibrotic' or 'sclerotic' stage with stenosis deformity and loss of functions of the parts affected. examples of commonly used drugs are 'rifampicin' which is the most commonly used drug exhibits good results but the need for close monitoring for fear of toxicity is the only limitation to its use, ciprofloxacin' is another antibiotic with special efficacy as it has good tissue penetration \& produces high concentrations in respiratory tract secretions. recently 'doxycycline' has been approved to be used in rhinoscleroma which has the advantage of not only easier dosing but also better patient compliance as it's used for a shorter course (6 weeks) compared to most other drugs.

Eligibility criteria:
inclusion criteria: * patients will be included after confirmation by histopathological examination. * patients presented in active stages of the disease. * patients between 18-70 years. exclusion criteria: * any granulomatous lesion or features suggestive of rhinoscleroma associated with any other nasal lesions like syphilis, leprosy and tuberculosis were excluded. * patients below 18 years and above 70 years. * biopsy-negative cases. * patients in atrophic or sclerotic stages of the disease.

Keywords: doxycycline
health benefits of expressive writing: study one

Conditions: Breast Cancer; Breast Neoplasm

Summary: this study is a randomized controlled trial (rct) with the aim of determining the cultural sensitivity, feasibility, and effectiveness of an expressive writing intervention for chinese breast cancer survivors.

the study examines the potential health benefits (i.e., physical health, psychological health, and quality of life) of this expressive writing intervention for chinese-speaking breast cancer survivors. the study also explores the mechanism through which expressive writing confers health benefits and investigates who will benefit most from the expressive writing intervention. chinese-speaking breast cancer survivors who have completed primary treatment will be randomly assigned to a control writing condition, a self-regulation condition, or an emotional disclosure writing condition. health outcomes are assessed at baseline, and 1, 3, and 6 months follow-ups. mixed qualitative-quantitative mixed methods are used to explore the effect of the intervention on health outcomes and explore the mechanisms that explain the benefits of this intervention.

Eligibility criteria:
inclusion criteria: * 1) having a breast cancer diagnosis * 2) completing primary medical treatment within four years * 3) being comfortable writing and speaking chinese (i.e. mandarin or cantonese)

Keywords: chinese breast cancer survivors expressive writing
a study of bg-c477 in participants with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of bg-c477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

this new study will check how safe and helpful a potential anticancer drug called bg-c477 is. this drug will be tested by itself or combined with other anticancer agents. the purpose of this study is to test if bg-c477 is safe and if it works in people with your disease when it is given on its own and in combination with other anticancer agents.

Eligibility criteria:
inclusion criteria: * participants must sign the informed consent form (icf) and be capable of giving written informed consent * participants must consent to provide an archival tumor tissue sample or a fresh baseline biopsy * phase 1a (dose escalation); histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors, who were previously treated with at least 2 lines of standard systemic therapy or for whom no standard treatment is available in the medical judgment of the investigator * ≥ 1 measurable lesion as assessed by recist v1.1 * stable eastern cooperative oncology group (ecog) performance status of ≤ 1 * adequate organ function * female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for ≥ 8 months after the last dose of bg-c477 and for ≥ 6 months after the last dose of chemotherapy, whichever comes later * nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for ≥ 5 months after the last dose of bg-c477, and for ≥ 3 months after chemotherapy, whichever comes later. exclusion criteria: * prior treatment with any carcinoembryonic antigen (cea)-targeted adcs or adcs containing topoisomerase 1 (top1) inhibitor as payload * history of severe allergic reactions, severe reaction to infusion, or hypersensitivity to the active ingredient and excipients of the study drug(s) or protein-based therapeutics * active leptomeningeal disease or uncontrolled, untreated brain metastasis * any malignancy ≤ 2 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast) note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: bg-c477 advanced solid tumors
discovering the gene(s) causing developmental dysplasia of the hip (ddh)

Conditions: Hip Dysplasia

Summary: the primary objective of the study is to find the gene(s) responsible for causing ddh. the secondary objective of the study is to determine the mode of genetic transmission of ddh.

developmental dysplasia of the hip (ddh), formerly known as congenital dislocation of the hip (cdh) is a relatively common disorder that can lead to early onset arthritis of the hip. it is believed that ddh is the major cause of arthritis of the hip in young patients. the majority of patients with ddh are unaware of their condition. only a very small number of these patients with the extremely severe form of the disease (dislocated hip) are identified at birth. the remaining patients usually seek help when severe arthritis is present and joint preservation treatment is not possible. the exact etiology of this condition remains elusive. based on reports in the literature, ddh is believed to have a genetic basis. dr. javad parvizi at rothman institute (rt) in philadelphia has extensive experience with this condition because their center provides joint preservation procedures such as pelvic and femoral osteotomy. they also have extensive experience with hip replacement in these patients. they are aware of some families with many affected individuals. close history taking and examination of these patients has suggested that there may indeed be a genetic basis for ddh. based on our findings so far, we believe that a dominant pattern of inheritance may exist, implying that this disorder may be inherited in a mendelian manner (single gene disorder). furthermore, dr. parvizi's group have documented a peculiar pattern of dominant inheritance in which all affected males give rise to only affected female children, suggesting that the disorder may be inherited as an x-linked dominant trait. x-linked dominant is the mode of inheritance in which a gene on the x chromosome is dominant. the x-linked dominant inheritance may in part account for the large number of females affected with the trait. understanding the inheritance mechanism of this disease will allow better genetic counseling and monitoring of affected individuals and their families. the reason behind this study is to investigate the possible genetic inheritance of the disease. knowing this information will allow us to test patients for the disease early and before arthritis develops. in addition it is possible that better treatments may be designed based on this knowledge. ddh is a relatively common condition. although the most severe form of ddh is usually diagnosed during birth (dislocated hip), the majority (\>80%) of patients with this condition do not even know that they suffer from this disease and usually discover their condition when disabling arthritis of the hip develops in early adulthood.

Eligibility criteria:
inclusion criteria: * all patients with radiographic and clinical diagnosis of ddh will be included. exclusion criteria: * other forms of arthritis: * osteoarthritis * inflammatory arthropathies * vascular necrosis